Introduction
Phthalates are chemical additives incorporated in PVCbased materials to make them more pliable. Intensive care management, especially in the pediatric setting, relies heavily on the use of soft and flexible indwelling medical devices. As phthalates are not chemically bound to these devices, they can leach during use [1, 2] . Environmental phthalate exposure has been associated with attention deficit disorders in children [3, 4] .
Objectives
We hypothesized that in children treated in the pediatric intensive care unit (PICU), phthalates leaching from the indwelling medical devices contribute to the important long-term attention deficit.
Methods
Plasma concentrations of di(2-ethylhexyl)phthalate (DEHP) metabolites were quantified in 100 healthy children and in 449 children who had been treated in PICU and were neurocognitively tested 4 years later. In a development patient cohort (N = 228), a multivariable bootstrap study identified the stable thresholds of the exposure to DEHP metabolites that appeared toxic for neurocognitive development. Subsequently, in a second patient cohort (N = 221), the observed independent associations were validated.
Results
Mean plasma concentrations of the DEHP metabolites were 45-to 280-times higher than normal upon PICU admission, decreased rapidly but remained 3-to 29-times elevated until PICU discharge (all P < 0.001). After adjusting for baseline risk factors and for duration of PICU stay, and further for complications occurring during PICU stay, exceeding the toxic threshold for exposure to the total DEHP metabolites was independently associated with the attention deficit (all P≤0.01) and with the impaired motor coordination (all P≤0.04). The association between phthalate exposure and the attention deficit was confirmed in the validation cohort (all P≤0.01). The size of these effects was the equivalent of 34%-68% of the differences between patients and controls.
Conclusions
Iatrogenic exposure to DEHP metabolites during intensive care was independently and robustly associated with the important attention deficit observed in children 4 years after pediatric critical illness.
Trial registration at ClinicalTrials.gov: NCT00214916 
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